Nuvation Bio Inc. Contract with Customer, Liability, Noncurrent
Nuvation Bio Inc. (NUVB) had Contract with Customer, Liability, Noncurrent of $13.61 million as of 2025-03-31, per its 10-Q filed 2025-05-07.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent › Deferred Revenue, Noncurrent
us-gaap:ContractWithCustomerLiabilityNoncurrent · last filed 2025-05-07
- 2025-03-31: Contract with Customer, Liability, Noncurrent $13.61M.
- 2024-12-31: Contract with Customer, Liability, Noncurrent $15.57M.
- 2024-09-30: Contract with Customer, Liability, Noncurrent $7.94M.
- 2024-06-30: Contract with Customer, Liability, Noncurrent $9.16M.
| Period end | Contract with Customer, Liability, Noncurrent |
|---|---|
| 2025-03-31 | $13.61M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $15.57M 10-Q · filed 2025-05-07 |
| 2024-09-30 | $7.94M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $9.16M 10-Q · filed 2024-08-05 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |